{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"141-314-636-236-188","frontPageModel":{"patentViewModel":{"ref":{"entityRefId":"141-314-636-236-188","entityRefType":"PATENT"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":8838,"type":"PATENT","title":"Univ of Illinois Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":10245,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8209,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately = \"Univ Illinois\", \"Illinois Univ\", \"University of Illinois\", \"Illinois University\", \"University Illinois NOT Northern NOT southern NOT State\".
Select more for logical variants
Add the result to Collection
Select the result and expand by simple families.
Add to collection
Total patents: 9630
Search Applicants and Owners separately: uni* illinois chicago
Select more for logical variants.
Add to collection.
Select all patents in the collection and expand by simple families.
Add to collection. Total patents: 4560
Search Applicants and Owners separately = \"Univ Illinois\", \"Illinois Univ\", \"University of Illinois\", \"Illinois University\", \"University Illinois NOT Northern NOT southern NOT State\".
Select more for logical variants
Add the result to Collection
Select the result and expand by simple families.
Add to collection
Total patents: 9630
Search Applicants and Owners separately: uni* illinois chicago
Select more for logical variants.
Add to collection.
Select all patents in the collection and expand by simple families.
Add to collection. Total patents: 4560
extracting umbilical cord blood comprising mononuclear cells;\n
culturing the mononuclear cells in growth medium, such that the mononuclear cells revert to embryonic-like stem cells;\n
isolating the embryonic-like stem cells."],"number":19,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 19, wherein the step of culturing further comprises seeding said mononuclear cells on a hydrophobic surface with a net positive charge."],"number":20,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 21, wherein said surface is selected from the group consisting of polystyrene and glass."],"number":21,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 20, wherein the step of isolating the embryonic-like stem cells comprises isolating said cells attached to the surface."],"number":22,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 20, wherein the step of isolating the embryonic-like stem cells further comprises selecting cell that have a positive marker for at least one of Octamer-binding transcription factor 4 (Oct-4), Nanog homeobox (Nanog), SRY (sex determining region Y)-box 2 (Sox-2), and CD45;\n
a negative marker for at least one of CD3, CD20, CD11c, CD11b/Mac-1, and CD14; and\n
a negative marker for CD 34."],"number":23,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 23, wherein the step of isolating the embryonic-like stem cells further comprises selecting for cells that have a positive marker for at least one of activated leukocyte cell adhesion molecule (ALCAM), complement component 5a receptor 1 (C5AR1), CD37, CD63, CD74, colony stimulating factor 1 receptor (CSF1R), integrin alpha 3, and myosin heavy chain 9 (non-muscle)."],"number":24,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 20, wherein the step of isolating the embryonic-like stem cells further comprises isolating a substantially homogeneous population of embryonic-like stem cells."],"number":25,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 22, wherein the step of isolating said cells attached to the surface further comprises incubating the cells with a solution comprising lidocaine hydrochloride."],"number":26,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 26, wherein the solution further comprises ethylenediamine tetraacetic acid (EDTA)."],"number":27,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 19, wherein the growth medium comprises RPMI 1640 medium and fetal bovine serum."],"number":28,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 19, wherein the step of extracting peripheral blood further comprises removing red cells from umbilical cord blood to obtain mononuclear cells."],"number":29,"annotation":false,"claim":true,"title":false},{"lines":["An isolated embryonic-like stem cell harvested from umbilical cord blood comprising:\n
a positive marker for at least one of Oct-4, Nanog, Sox-2, and CD45,\n
a negative marker for at least one of CD3, CD20, CD11c, CD11b/Mac-1, and CD14;\n
and a negative marker for CD 34."],"number":30,"annotation":false,"claim":true,"title":false},{"lines":["The isolated embryonic-like stem cell of claim 30, wherein said cell is capable of differentiating into insulin-producing cells."],"number":31,"annotation":false,"claim":true,"title":false},{"lines":["The isolated embryonic-like stem cell of claim 31, wherein the insulin-producing cells expresses at least one insulin gene transcription factor."],"number":32,"annotation":false,"claim":true,"title":false},{"lines":["The isolated embryonic-like stem cell of claim 31, wherein at least one insulin gene transcription factor is selected from the group consisting of leucine zipper MafA, Pdx-1 (pancreatic duodenal homeobox factor 1), NeuroD1 (neurogenic differentiation 1), HNF6 (hepatocyte nuclear factor 6), Nkx6.1 (Nk homeobox gene), and Nkx2.2."],"number":33,"annotation":false,"claim":true,"title":false},{"lines":["The isolated embryonic-like stem cell of claim 31, wherein the cell further comprises at least one of the following embryonic genes selected from the group consisting of Zinc finger protein 206 (ZNF206), Zic family member 3 heterotaxy 1 (ZIC3), Zic family member 2 (ZIC2), Growth associated protein 43 (GAP43), PR domain containing 14 (PRDM14), Protein tyrosine phosphatase, receptor-type, Z polypeptide 1 (PTPRZ1), Podocalyxin-like (PODXL), and Zinc finger protein 589 (ZNF589)."],"number":34,"annotation":false,"claim":true,"title":false},{"lines":["The isolated embryonic-like stem cell of claim 31, wherein the cell further comprises at least one positive marker selected from the group consisting of activated leukocyte cell adhesion molecule (ALCAM), complement component 5a receptor 1 (C5AR1), CD37, CD63, CD74, colony stimulating factor 1 receptor (CSF1R), integrin alpha 3, and myosin heavy chain 9 (non-muscle)."],"number":35,"annotation":false,"claim":true,"title":false},{"lines":["A method of suppressing lymphocytes in a subject in need thereof, comprising\n
culturing a first population of cells comprising embryonic-like stem cells with a second population of cells comprising lymphocytes,\n
administering at least one of the first or second cell populations to a subject."],"number":36,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 36, wherein said administering step comprises administering the second cell population."],"number":37,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 36, wherein the method further comprises isolating lymphocytes following the step of coculturing with the embryonic-like stem cells, wherein the isolated lymphocytes are positive for the marker CD62L+, and are positive for a marker selected from the group CD4+, CD8+, CD3+, and CD19+."],"number":38,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 36, wherein the method further comprises increasing insulin production in the subject."],"number":39,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 38, wherein the method further comprises administering a population expressing positive markers for CD8 and CD62L,"],"number":40,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 40, wherein the method comprises delaying onset of diabetes in a subject at risk thereof."],"number":41,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 38, wherein the method further comprises administering a population expressing positive markers for CD4 and CD62L."],"number":42,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 40, wherein the method comprises ameliorating diabetes in a subject."],"number":43,"annotation":false,"claim":true,"title":false},{"lines":["A method of treating diabetes in a mammalian subject in need thereof, comprising\n
culturing embryonic-like stem cells from umbilical cord blood; and\n
administering said cells to the subject in an amount effective to treat diabetes."],"number":44,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 44, wherein said administering step is carried out by intraperitoneal injection."],"number":45,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 44, wherein said diabetes is insulin-dependent diabetes."],"number":46,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 44, wherein the method further comprising co-culturing the embryonic-like stem cells with lymphocytes, isolating the lymphocytes that are positive for the marker CD62L, and are positive for a marker selected from the group CD4, CD8, CD3, and CD19, administering at least one population of the isolated lymphocytes with the embryonic-like stem cells."],"number":47,"annotation":false,"claim":true,"title":false},{"lines":["A method for preventing or treating or treating an autoimmune disease in a mammalian subject, the method comprising administering an effective amount of the embryonic-like stem cells from human umbilical-cord blood (CB-SC) of claim 30 to the subject."],"number":48,"annotation":false,"claim":true,"title":false},{"lines":["The method of claim 48, wherein the autoimmune disease is type 1 diabetes."],"number":49,"annotation":false,"claim":true,"title":false}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}